Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) and Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Alnylam Pharmaceuticals and Atea Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alnylam Pharmaceuticals | 1 | 5 | 18 | 0 | 2.71 |
| Atea Pharmaceuticals | 0 | 1 | 0 | 1 | 3.00 |
Alnylam Pharmaceuticals presently has a consensus price target of $298.09, suggesting a potential upside of 24.79%. Atea Pharmaceuticals has a consensus price target of $6.88, suggesting a potential upside of 119.81%. Given Atea Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Atea Pharmaceuticals is more favorable than Alnylam Pharmaceuticals.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Alnylam Pharmaceuticals | -15.86% | N/A | -8.38% |
| Atea Pharmaceuticals | N/A | -34.90% | -32.38% |
Insider and Institutional Ownership
93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are held by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 17.8% of Atea Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Alnylam Pharmaceuticals and Atea Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alnylam Pharmaceuticals | $2.09 billion | 14.71 | -$440.24 million | ($2.62) | -91.17 |
| Atea Pharmaceuticals | $351.37 million | 0.75 | -$135.96 million | ($2.07) | -1.51 |
Atea Pharmaceuticals has lower revenue, but higher earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Alnylam Pharmaceuticals has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500. Comparatively, Atea Pharmaceuticals has a beta of 0.2, indicating that its share price is 80% less volatile than the S&P 500.
Summary
Atea Pharmaceuticals beats Alnylam Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
About Atea Pharmaceuticals
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
